Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease
Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K, Mizusawa H, Ishii K. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease. Acta Neurol Scand: 2010: 122: 46–51. © 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard. Objectives – ...
Gespeichert in:
| Veröffentlicht in: | Acta neurologica Scandinavica 2010-07, Vol.122 (1), p.46-51 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 46 |
| container_title | Acta neurologica Scandinavica |
| container_volume | 122 |
| creator | Ishibashi, K. Kanemaru, K. Saito, Y. Murayama, S. Oda, K. Ishiwata, K. Mizusawa, H. Ishii, K. |
| description | Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K, Mizusawa H, Ishii K. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease.
Acta Neurol Scand: 2010: 122: 46–51.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard.
Objectives – To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐tropane (11C‐CFT), which can measure the dopamine transporter (DAT) density, in Parkinson’s disease (PD).
Methods – 11C‐CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non‐parkinsonian syndromes (NPS) as a control group.
Results – In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C‐CFT (r = 0.76, P |
| doi_str_mv | 10.1111/j.1600-0404.2009.01255.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_746078761</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746078761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4195-50a4e95e87d36199fd61fa19761012a33f33ff5c98a87643c933b2356aa9ed4b3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhLyBfUE8J4_hrfeBQrUr5qApIfJyQNUmcykviLHYitv8eh12WI5atGWuedzSalxDKoGT5vNyWTAEUIECUFYApgVVSlvsHZHUqPCQrAGCF4kyckScpbfOv0kI8JmdZA_npFfm-cdHVcUw7H7CnXT_7lg5uwnrs_eQohpYGf5eBKXqcMtKOOxx8cPHON7SbQzP5MVAf6EeMP3xIY7hItPXJYXJPyaMO--SeHeM5-fL66vPmTXHz4frt5vKmaAQzspCAwhnp1rrlihnTtYp1yIxWLI-MnHf5drIxa1xrJXhjOK8rLhWica2o-Tm5OPTdxfHn7NJkB58a1_cY3Dgnq4UCnaXs_yTnioMGk8nnR3KuB9faXfQDxnv7d3cZeHEEMDXYdxFD49M_rlorJgEy9-rA_fK9uz_VGdjFS7u1i2V2sWzpbewfL-3eXt5eLVnWFwe9T5Pbn_R521ZprqX9dntt3xv-VXx6V1nFfwOubqAc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733630709</pqid></control><display><type>article</type><title>Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ishibashi, K. ; Kanemaru, K. ; Saito, Y. ; Murayama, S. ; Oda, K. ; Ishiwata, K. ; Mizusawa, H. ; Ishii, K.</creator><creatorcontrib>Ishibashi, K. ; Kanemaru, K. ; Saito, Y. ; Murayama, S. ; Oda, K. ; Ishiwata, K. ; Mizusawa, H. ; Ishii, K.</creatorcontrib><description>Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K, Mizusawa H, Ishii K. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease.
Acta Neurol Scand: 2010: 122: 46–51.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard.
Objectives – To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐tropane (11C‐CFT), which can measure the dopamine transporter (DAT) density, in Parkinson’s disease (PD).
Methods – 11C‐CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non‐parkinsonian syndromes (NPS) as a control group.
Results – In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C‐CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range.
Conclusions – In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.</description><identifier>ISSN: 0001-6314</identifier><identifier>EISSN: 1600-0404</identifier><identifier>DOI: 10.1111/j.1600-0404.2009.01255.x</identifier><identifier>PMID: 20002007</identifier><identifier>CODEN: ANRSAS</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>11C-CFT ; Aged ; Aged, 80 and over ; Basal Ganglia - diagnostic imaging ; Basal Ganglia - metabolism ; Biological and medical sciences ; cerebrospinal fluid ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Dopamine - metabolism ; Dopamine Plasma Membrane Transport Proteins - metabolism ; dopamine transporter ; Female ; homovanillic acid ; Homovanillic Acid - cerebrospinal fluid ; Humans ; Male ; Medical sciences ; Middle Aged ; Neurology ; Parkinson Disease - cerebrospinal fluid ; Parkinson Disease - diagnosis ; Parkinson Disease - physiopathology ; Parkinson's disease ; Positron-Emission Tomography ; Retrospective Studies</subject><ispartof>Acta neurologica Scandinavica, 2010-07, Vol.122 (1), p.46-51</ispartof><rights>Copyright © 2009 The Authors. Journal compilation © 2009 Blackwell Munksgaard</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4195-50a4e95e87d36199fd61fa19761012a33f33ff5c98a87643c933b2356aa9ed4b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0404.2009.01255.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0404.2009.01255.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22861500$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20002007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishibashi, K.</creatorcontrib><creatorcontrib>Kanemaru, K.</creatorcontrib><creatorcontrib>Saito, Y.</creatorcontrib><creatorcontrib>Murayama, S.</creatorcontrib><creatorcontrib>Oda, K.</creatorcontrib><creatorcontrib>Ishiwata, K.</creatorcontrib><creatorcontrib>Mizusawa, H.</creatorcontrib><creatorcontrib>Ishii, K.</creatorcontrib><title>Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease</title><title>Acta neurologica Scandinavica</title><addtitle>Acta Neurol Scand</addtitle><description>Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K, Mizusawa H, Ishii K. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease.
Acta Neurol Scand: 2010: 122: 46–51.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard.
Objectives – To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐tropane (11C‐CFT), which can measure the dopamine transporter (DAT) density, in Parkinson’s disease (PD).
Methods – 11C‐CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non‐parkinsonian syndromes (NPS) as a control group.
Results – In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C‐CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range.
Conclusions – In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.</description><subject>11C-CFT</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Basal Ganglia - diagnostic imaging</subject><subject>Basal Ganglia - metabolism</subject><subject>Biological and medical sciences</subject><subject>cerebrospinal fluid</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Dopamine - metabolism</subject><subject>Dopamine Plasma Membrane Transport Proteins - metabolism</subject><subject>dopamine transporter</subject><subject>Female</subject><subject>homovanillic acid</subject><subject>Homovanillic Acid - cerebrospinal fluid</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Parkinson Disease - cerebrospinal fluid</subject><subject>Parkinson Disease - diagnosis</subject><subject>Parkinson Disease - physiopathology</subject><subject>Parkinson's disease</subject><subject>Positron-Emission Tomography</subject><subject>Retrospective Studies</subject><issn>0001-6314</issn><issn>1600-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhi0EokvhLyBfUE8J4_hrfeBQrUr5qApIfJyQNUmcykviLHYitv8eh12WI5atGWuedzSalxDKoGT5vNyWTAEUIECUFYApgVVSlvsHZHUqPCQrAGCF4kyckScpbfOv0kI8JmdZA_npFfm-cdHVcUw7H7CnXT_7lg5uwnrs_eQohpYGf5eBKXqcMtKOOxx8cPHON7SbQzP5MVAf6EeMP3xIY7hItPXJYXJPyaMO--SeHeM5-fL66vPmTXHz4frt5vKmaAQzspCAwhnp1rrlihnTtYp1yIxWLI-MnHf5drIxa1xrJXhjOK8rLhWica2o-Tm5OPTdxfHn7NJkB58a1_cY3Dgnq4UCnaXs_yTnioMGk8nnR3KuB9faXfQDxnv7d3cZeHEEMDXYdxFD49M_rlorJgEy9-rA_fK9uz_VGdjFS7u1i2V2sWzpbewfL-3eXt5eLVnWFwe9T5Pbn_R521ZprqX9dntt3xv-VXx6V1nFfwOubqAc</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>Ishibashi, K.</creator><creator>Kanemaru, K.</creator><creator>Saito, Y.</creator><creator>Murayama, S.</creator><creator>Oda, K.</creator><creator>Ishiwata, K.</creator><creator>Mizusawa, H.</creator><creator>Ishii, K.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>201007</creationdate><title>Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease</title><author>Ishibashi, K. ; Kanemaru, K. ; Saito, Y. ; Murayama, S. ; Oda, K. ; Ishiwata, K. ; Mizusawa, H. ; Ishii, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4195-50a4e95e87d36199fd61fa19761012a33f33ff5c98a87643c933b2356aa9ed4b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>11C-CFT</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Basal Ganglia - diagnostic imaging</topic><topic>Basal Ganglia - metabolism</topic><topic>Biological and medical sciences</topic><topic>cerebrospinal fluid</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Dopamine - metabolism</topic><topic>Dopamine Plasma Membrane Transport Proteins - metabolism</topic><topic>dopamine transporter</topic><topic>Female</topic><topic>homovanillic acid</topic><topic>Homovanillic Acid - cerebrospinal fluid</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Parkinson Disease - cerebrospinal fluid</topic><topic>Parkinson Disease - diagnosis</topic><topic>Parkinson Disease - physiopathology</topic><topic>Parkinson's disease</topic><topic>Positron-Emission Tomography</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishibashi, K.</creatorcontrib><creatorcontrib>Kanemaru, K.</creatorcontrib><creatorcontrib>Saito, Y.</creatorcontrib><creatorcontrib>Murayama, S.</creatorcontrib><creatorcontrib>Oda, K.</creatorcontrib><creatorcontrib>Ishiwata, K.</creatorcontrib><creatorcontrib>Mizusawa, H.</creatorcontrib><creatorcontrib>Ishii, K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Acta neurologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishibashi, K.</au><au>Kanemaru, K.</au><au>Saito, Y.</au><au>Murayama, S.</au><au>Oda, K.</au><au>Ishiwata, K.</au><au>Mizusawa, H.</au><au>Ishii, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease</atitle><jtitle>Acta neurologica Scandinavica</jtitle><addtitle>Acta Neurol Scand</addtitle><date>2010-07</date><risdate>2010</risdate><volume>122</volume><issue>1</issue><spage>46</spage><epage>51</epage><pages>46-51</pages><issn>0001-6314</issn><eissn>1600-0404</eissn><coden>ANRSAS</coden><abstract>Ishibashi K, Kanemaru K, Saito Y, Murayama S, Oda K, Ishiwata K, Mizusawa H, Ishii K. Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease.
Acta Neurol Scand: 2010: 122: 46–51.
© 2009 The Authors Journal compilation © 2009 Blackwell Munksgaard.
Objectives – To evaluate the association between cerebrospinal fluid (CSF) homovanillic acid (HVA) concentrations and nigrostriatal dopaminergic function assessed by positron emission tomography (PET) imaging with carbon‐11‐labeled 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐tropane (11C‐CFT), which can measure the dopamine transporter (DAT) density, in Parkinson’s disease (PD).
Methods – 11C‐CFT PET scans and CSF examinations were performed on 21 patients with PD, and six patients with non‐parkinsonian syndromes (NPS) as a control group.
Results – In the PD group, CSF HVA concentrations were significantly correlated with the striatal uptake of 11C‐CFT (r = 0.76, P < 0.01). However, in the NPS group, two indices were within the normal range.
Conclusions – In PD, CSF HVA concentrations correlate with nigrostriatal dopaminergic function. Therefore, CSF HVA concentrations may be an additional surrogate marker for estimating the remaining nigrostriatal dopaminergic function in case that DAT imaging is unavailable.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20002007</pmid><doi>10.1111/j.1600-0404.2009.01255.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6314 |
| ispartof | Acta neurologica Scandinavica, 2010-07, Vol.122 (1), p.46-51 |
| issn | 0001-6314 1600-0404 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746078761 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | 11C-CFT Aged Aged, 80 and over Basal Ganglia - diagnostic imaging Basal Ganglia - metabolism Biological and medical sciences cerebrospinal fluid Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dopamine - metabolism Dopamine Plasma Membrane Transport Proteins - metabolism dopamine transporter Female homovanillic acid Homovanillic Acid - cerebrospinal fluid Humans Male Medical sciences Middle Aged Neurology Parkinson Disease - cerebrospinal fluid Parkinson Disease - diagnosis Parkinson Disease - physiopathology Parkinson's disease Positron-Emission Tomography Retrospective Studies |
| title | Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A25%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cerebrospinal%20fluid%20metabolite%20and%20nigrostriatal%20dopaminergic%20function%20in%20Parkinson's%20disease&rft.jtitle=Acta%20neurologica%20Scandinavica&rft.au=Ishibashi,%20K.&rft.date=2010-07&rft.volume=122&rft.issue=1&rft.spage=46&rft.epage=51&rft.pages=46-51&rft.issn=0001-6314&rft.eissn=1600-0404&rft.coden=ANRSAS&rft_id=info:doi/10.1111/j.1600-0404.2009.01255.x&rft_dat=%3Cproquest_pubme%3E746078761%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733630709&rft_id=info:pmid/20002007&rfr_iscdi=true |